In accordance
with 5 CFR 1320, the information collection is not approved at this
time. Prior to publication of the final rule, the agency should
provide to OMB a summary of all comments received on the proposed
information collection and identify any changes made in response to
these comments.
Inventory as of this Action
Requested
Previously Approved
36 Months From Approved
0
0
0
0
0
0
0
0
0
This ICR supports our proposed
regulation implementing reporting requirements of the Trickett
Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right
to Try Act of 2017 (Right to Try Act). The requirements would
establish deadlines, frequency, and content of submissions for
manufacturers who provide an eligible investigational drug for use
by patients who meet certain criteria as set forth under the Right
to Try Act.
This is a new information
collection to implement new statutory requirements.
$284,299
No
Yes
No
No
No
No
No
Domini Bean 301 796-5733
domini.bean@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.